Tresiba Cost in Arkansas 2026: Insulin Degludec Prices, Coverage, and Savings

What Does Tresiba Actually Cost in Arkansas in 2026?

The sticker price for Tresiba is roughly $510 per month before any discounts, but most Arkansas patients pay far less. At retail pharmacies across the state, GoodRx and similar discount platforms bring the average cash price down to approximately $35 per month for a standard 30-day supply of insulin degludec 100 U/mL FlexTouch pens. Commercially insured patients who qualify for the Novo Nordisk Patient Assistance or savings-card programs can pay $0 to $99 per month depending on their plan tier.

The gap between the $510 list price and the $35 cash price exists because pharmacy benefit managers negotiate rebates directly with Novo Nordisk. Those rebates do not always flow to the patient at the counter. If your plan places Tresiba on a non-preferred tier, you may face a higher copay than the uninsured cash price, making it worth running a coupon check before every fill.

Tresiba (insulin degludec) received FDA approval in September 2015 for adults with type 1 and type 2 diabetes [1]. The key DEVOTE trial (N=7,637) demonstrated that degludec produced significantly fewer severe hypoglycemic episodes compared with insulin glargine U-100 (hazard ratio 0.60 to 95% CI 0.48, 0.76, P<0.001 for superiority) while maintaining non-inferior cardiovascular outcomes [2]. That safety profile is part of why clinicians in Arkansas and nationally favor it despite the cost barrier.

Price checks should be run at GoodRx.com, Blink Health, or directly through the Novo Nordisk NovoCare portal, because Arkansas pharmacy pricing varies by ZIP code. A patient in Little Rock may see a different cash price than one in Fayetteville or Jonesboro.

Arkansas Medicaid Coverage for Tresiba: Prior Authorization Requirements

Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers insulin degludec on its preferred drug list under a limited prior-authorization (PA) pathway for both type 1 and type 2 diabetes. "Limited PA" means the drug is on formulary but your prescriber must submit documentation before the first fill is approved.

The PA criteria typically require evidence that the patient has had recurrent hypoglycemia or documented inadequate glycemic control on a formulary basal insulin such as insulin glargine or insulin detemir [3]. Arkansas Medicaid follows the American Diabetes Association (ADA) Standards of Medical Care, which state: "Basal insulin analogs with lower hypoglycemia risk... should be considered for patients with recurrent hypoglycemia" [4]. That language is the clinical basis most prescribers use to justify the PA.

Step-therapy is common. The PA reviewer will look for a trial of at least one preferred basal insulin lasting 90 days unless a clinical contraindication exists. Approvals are typically valid for 12 months and renewable annually.

If your first PA is denied, Arkansas Medicaid's appeals process allows a prescriber to request a Standard or Expedited Appeal. Expedited appeals must be resolved within 72 hours when a delay would seriously jeopardize health. Patients enrolled in Arkansas Medicaid Managed Care Organizations (MCOs) such as AmeriHealth Caritas Arkansas must go through their MCO's PA pathway, which may differ slightly from fee-for-service Medicaid requirements [5].

Medicaid beneficiaries should ask their endocrinologist or primary care provider to submit the PA with a detailed clinical note documenting hypoglycemic episodes, blood glucose logs, and prior insulin trials. That documentation package is the single biggest factor in first-attempt approval rates.

Is Compounded Insulin Degludec Legal in Arkansas?

Compounded insulin degludec is available through licensed 503A compounding pharmacies in Arkansas. It is not FDA-approved as a compounded product, so its use requires a valid patient-specific prescription from a licensed prescriber [6].

Under federal law (21 U.S.C. 503A), a 503A pharmacy may compound insulin degludec for an individual patient if a licensed practitioner issues a prescription for that specific patient and the compound is not commercially available in the required strength or form. Arkansas follows federal 503A standards and adds state-level oversight through the Arkansas State Board of Pharmacy [7]. Pharmacies operating as 503B outsourcing facilities are held to a different, stricter standard and would not typically compound a commercially available drug like Tresiba without FDA placement on the drug-shortage list.

Practically speaking, the cost advantage of compounded insulin degludec can be significant. Where a licensed Arkansas 503A pharmacy dispenses it, some patients report $0 out-of-pocket through telehealth platforms that bundle the compounding cost. However, compounded insulin is not bioequivalent-certified by the FDA, which means the potency, sterility, and stability may differ from the branded product [6]. The FDA has issued guidance noting that compounded drug products "lack an FDA finding of safety, effectiveness, or manufacturing quality" [6]. Patients switching from branded Tresiba to a compounded degludec formulation should monitor blood glucose closely for the first two weeks.

Prescribers should verify that any Arkansas 503A pharmacy they refer patients to is in good standing with the Arkansas State Board of Pharmacy before writing a compounding-directed prescription.

Which Insurance Plans Cover Tresiba in Arkansas?

Coverage varies by plan type, formulary tier, and benefit year. The three main categories Arkansas patients encounter are commercial insurance, Arkansas Medicaid, and Medicare Part D.

Commercial insurance. Most major commercial plans sold on the Arkansas Health Insurance Marketplace (ACA exchange) include at least one basal insulin analog on formulary. Tresiba's tier placement depends on the insurer. BlueCross BlueShield of Arkansas, QualChoice, and Ambetter from Home State Health each maintain separate PDLs updated annually. Tresiba appears as a Tier 3 or Tier 4 non-preferred drug on several 2026 Arkansas plan PDLs, meaning a copay of $60, $120 per fill before the deductible is met. Patients on these plans often pay less by using the Novo Nordisk savings card on a cash-pay basis than by running the prescription through insurance [8].

Medicare Part D. Medicare does not cap insulin costs above $35 per month per the Inflation Reduction Act insulin provision, which took effect January 1, 2023. Arkansas Medicare beneficiaries should pay no more than $35 per fill of Tresiba on any Part D plan, provided the plan includes it on formulary [9]. If your plan does not cover Tresiba, request a formulary exception citing medical necessity and supporting the request with DEVOTE trial data on hypoglycemia reduction.

Arkansas Medicaid. Covered with prior authorization as described above.

The table below summarizes 2026 typical out-of-pocket ranges by coverage type for a standard 30-day supply:

| Coverage Type | Typical OOP Range (2026) | |---|---| | No insurance, no coupon | ~$510 | | No insurance, GoodRx coupon | ~$35 | | Commercial (Tier 3), no savings card | $60, $120 | | Commercial + Novo Nordisk savings card | $0, $99 | | Medicare Part D (post-IRA cap) | $35 | | Arkansas Medicaid (approved PA) | $0, $4 copay | | 503A compounded (telehealth program) | $0, $60 |

The Novo Nordisk Savings Card and Patient Assistance Program

Novo Nordisk operates two separate cost-reduction pathways for Tresiba: the NovoCare Savings Offer and the Patient Assistance Program (PAP).

The NovoCare Savings Offer is for commercially insured patients only. Eligible patients pay as little as $0 per month, with a maximum savings of $250 per prescription fill. The card is not valid for patients covered by any government program, including Arkansas Medicaid, Medicare, or TRICARE [10]. Income thresholds do not apply to the savings offer, only insurance type.

The Patient Assistance Program covers uninsured or underinsured patients who meet income criteria. In 2026, PAP eligibility generally requires household income at or below 400% of the federal poverty level and no current prescription drug coverage for insulin. Arkansas patients apply through the NovoCare portal or by calling 1-833-NOVO-411. Processing takes 4 to 8 weeks, so patients should not wait until they run out of insulin to apply.

A third option exists for short-term gaps: the Novo Nordisk Urgent Need Program provides a 90-day emergency supply at no cost for patients who cannot afford their insulin and meet income guidelines [10]. That program requires a prescriber signature and documentation of financial hardship.

The ADA's 2024 Standards of Medical Care state: "Clinicians should be knowledgeable about programs that provide access to insulin for patients who cannot afford it and should direct patients to these resources" [4]. Arkansas prescribers can find a current list of assistance programs through the ADA's Insulin Help hub at diabetes.org.

Telehealth Prescribing of Tresiba in Arkansas

Telehealth prescribing of Tresiba is legal in Arkansas for established patients. The Arkansas Telehealth Act (Act 203 of 2015, amended subsequently) requires that prescribers establish a valid patient-physician relationship before prescribing, and that relationship may be established via synchronous audio-video telemedicine [11].

Controlled substances have a separate federal requirement (the Ryan Haight Act, with DEA Special Registration for telemedicine), but insulin degludec is not a controlled substance. This means a licensed Arkansas prescriber can initiate a Tresiba prescription after a telemedicine visit without any special DEA registration or in-person prerequisite visit, as long as they conduct a clinically adequate evaluation [11].

Telehealth platforms such as HealthRX, Teladoc, or endocrinology-specific services can prescribe Tresiba and route the prescription to any Arkansas retail pharmacy or to a licensed 503A compounding pharmacy. Patients in rural Arkansas counties with limited endocrinology access, including areas like the Delta region, benefit most from this pathway.

Prescribers conducting telemedicine visits for insulin management should obtain: a current HbA1c (within 90 days), a fasting glucose log, documentation of prior insulin regimens, and a current medication list to check for interactions. The ADA recommends HbA1c testing at least twice yearly for patients meeting treatment goals, and quarterly for those not at goal [4].

Clinical Profile of Insulin Degludec: Why Prescribers Choose It

Insulin degludec is an ultra-long-acting basal insulin with a duration of action exceeding 42 hours, compared to approximately 24 hours for insulin glargine U-300 [12]. Its flat, peakless pharmacokinetic profile allows a flexible dosing window of 8 to 40 hours between injections without loss of glycemic control, a property tested in a dedicated flexible-dosing substudy of the BEGIN trials [13].

The DEVOTE trial enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk and randomized them to degludec or glargine U-100. After 2 years, degludec was non-inferior to glargine for the primary three-point MACE outcome (HR 0.91 to 95% CI 0.78, 1.06) and superior for severe hypoglycemia, with a 40% reduction in rate (rate ratio 0.60, P<0.001) [2]. That hypoglycemia benefit is especially relevant for Arkansas patients who are older, have impaired renal function, or live alone.

For type 1 diabetes, the BEGIN BASAL-BOLUS Type 1 trial (N=629) showed degludec plus aspart achieved HbA1c reduction of 0.40% from baseline vs. 0.39% for glargine plus aspart, with fewer confirmed nocturnal hypoglycemic episodes (rate ratio 0.75, P<0.038) [14].

Standard adult dosing is 10 units once daily at any time of day, titrated upward by 2 units every 3 days to a fasting glucose target of 80 to 100 mg/dL. Dose conversion from glargine is 1:1 (unit for unit) when switching from glargine U-100 [1]. Renal dose adjustment is not required, but close monitoring is warranted in patients with CrCl <30 mL/min because hypoglycemia risk rises with renal impairment [1].

Switching to Tresiba from Other Basal Insulins: Practical Steps

Switching from another basal insulin to Tresiba is straightforward but requires attention to timing and dose.

Patients coming from insulin glargine U-100 or detemir convert unit-for-unit. Patients switching from glargine U-300 should expect the prescriber to reduce the starting degludec dose by 20% because degludec is more bioavailable per unit than U-300 [1]. The FDA label states: "When converting from other basal insulins, a dose adjustment may be needed" and recommends closer monitoring during the transition period [1].

Blood glucose should be checked fasting for the first 7 days after the switch. HbA1c rechecked at 3 months will confirm whether the dose is adequate. Patients who experience more-frequent hypoglycemia after switching from U-300 to degludec may need a further 10% dose reduction at the 2-week mark.

Arkansas patients receiving Tresiba via telehealth prescribers should have a clear escalation plan: if fasting glucose exceeds 180 mg/dL for three consecutive days, they should contact their prescriber for a dose-titration message or call visit rather than self-adjusting by more than 2 units at a time [4].

The Cheapest Pathway to Tresiba in Arkansas: A Decision Guide

The least expensive route depends entirely on your insurance status.

No insurance: Use a GoodRx or Blink Health coupon at a high-volume retailer such as Walmart, Costco, or Walgreens in Arkansas. Target price is $35 per month. If income qualifies, apply to the Novo Nordisk PAP for ongoing supply.

Commercial insurance, Tresiba on non-preferred tier: Check whether the cash price plus the Novo Nordisk savings card is lower than your tier copay. For many Tier 3 plans, it is.

Medicare Part D: Pay $35 per fill under the IRA cap. No savings card needed.

Arkansas Medicaid: Submit a PA with clinical documentation of hypoglycemia or glargine failure. Approval results in a $0, $4 copay.

Interested in compounded degludec: Obtain a telehealth visit with a licensed Arkansas prescriber, confirm the 503A pharmacy is licensed by the Arkansas State Board of Pharmacy, and discuss the difference in FDA oversight compared to branded Tresiba with your provider [6].

Patients should not ration insulin under any circumstances. The ADA and American Heart Association have jointly stated that insulin rationing is associated with diabetic ketoacidosis and preventable hospitalizations [15]. If cost is a barrier today, the Novo Nordisk Urgent Need Program and community health centers in Arkansas (many of which operate on a sliding-scale fee basis under HRSA funding) can bridge access gaps within 24 to 72 hours [10].